W135 in Africa: Origins, problems and perspectives

Travel Medicine and Infectious Disease

Volumn 1, Issue 1, 2003, Pages 19-28

  Kelly, Dominic ^a   Pollard, Andrew J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Africa; Clonal complex; Epidemiology; Meningitis; Meningitis belt; Neisseria meningitidis; Vaccine

Indexed keywords

GLYCOCONJUGATE; MENINGOCOCCUS VACCINE; OUTER MEMBRANE PROTEIN; POLYSACCHARIDE VACCINE;

AFRICA; ANTIBIOTIC RESISTANCE; BACTERIAL VIRULENCE; BACTERIUM ISOLATE; CLONE; COST BENEFIT ANALYSIS; CROSS REACTION; DISEASE TRANSMISSION; EPIDEMIC; GENETIC TRANSFORMATION; GENETIC VARIABILITY; HEALTH SURVEY; HOUSEKEEPING GENE; HUMAN; INCIDENCE; MENINGOCOCCOSIS; MULTILOCUS ENZYME ELECTROPHORESIS; NEISSERIA LACTAMICA; NEISSERIA MENINGITIDIS; PATHOGENICITY; PRIORITY JOURNAL; REVIEW; SEASONAL VARIATION; VACCINATION;

EID: 15944414170     PISSN: 14778939     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1477-8939(03)00019-X     Document Type: Article

References (63)

1. Greenwood B. Meningococcal meningitis in Africa. Manson lecture. Trans R Soc Topics Med Hyg 1999;93:341-353.
2. Lapeyssonie L. La meningite cerebro-spinale en Afrique. Bull WHO 1963;281(Suppl. 1):3-114.
3. Molesworth AM, Thomson MC, Conno SJ, et al. Where is the meningitis belt? Defining an area at risk of epidemic meningitis in Africa. Trans R Soc Trop Ed Hyg 2002;96(3):242-249.
4. Aguilera J, Perrocheau A, Meffre C, Hahne S. Outbreak of serogroup w135 meningococcal disease after the Haj pilgrimage, Europe, 2000. Emerg Infect Dis 2002;8:761-767.
5. Hahne SJ, Gray SJ, Aguilera J-F, Crowcroft NS, Nichols T, Kaczmarski EB, Ramsay M. W135 meningococcal disease in England and Wales associated with Hajj 2000 and 2001. Lancet 2002;359:582-583.
6. WHO, Meningococcal disease, serogroup W135, Burkina Faso: preliminary report 2002. Wkly Epidemiol Rec 2002;77:152-155.
7. Feil EJ, Maiden MCJ, Actman M, Spratt BG. The relative contributions of recombination and mutation to the divergence of clones of Neisseria meningitidis. Mol Biol Evol 1999;16:1496-1502.
8. Chongaile CN. Meningitis in Africa-tackling W135. Lancet 2002;360:2054-2055.
9. Pollard AJ, Levin M. Vaccines for the prevention of meningococcal disease. Pediatr Infect Dis J 2000;19:333-345.
10. Swartley JS, Marfin AA, Edupuganti S, Liu L-J, Cieslak P, Perkins B, Wenger JD, Stephens DS. Capsule switching of Neisseria meningitidis. Proc Natl Acad Sci USA 1997;94:271-276.
11. Mayer L, Reeves MW, Al-Hamdan N, Sacchi CT, Taha M, et al. Outbreak of W135 meningococcal disease in 2000: not emergence of a new W135 strain but clonal expansion within the electrophoretic type-37 complex. J Infect Dis 2002;185:1596-1605.
12. Linz B, Schenker M, Peixan Z, Achtman M. Frequent interspecific genetic exchange between commensal neisseriae and Neisseria meningitidis. Mol Microbiol 2000;36(5):1049-1061.
13. Frasch CE, Zollinger WD, Poolman JT. Serotpye antigens of Neisseria meningitidis and a proposed scheme for the designation of serotypes. Rev Infect Dis 1985;7:504-510.
14. Caugant DA. Population genetics and molecular epidemiology of Neisseria meningitidis. APMIS 1998;106:505-525.
15. Selander RK, Caugant DA, Ochman H, Musser JM, GilmourMN, Wittam TS. Methods of multilocus enzyme electrophoresis for bacterial population genetics and systematics. Appl Environ Microbiol 1986;51:837-884.
16. Bygraves JA, Maiden MCJ. Analysis of the clonal relationships between strains of Neisseria meningitidis by pulsed field gel electrophoresis. J Gen Microbiol 1992;138:523-531.
17. Maiden MCJ, Bygraves JA, Feil E, Morelli G, Russel JE, Urwin R, et al. Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic organisms. Proc Natl Acad Sci USA 1998;95:3140-3145.
18. Achtman M. Global epidemiology. In: Cartwright K, editor. Meningococcal disease, 1st ed. Chichester: Wiley; 1995. p. 159-175.
19. Zhu P, van der Ende A, Falush D, Brieske N, Morelli G, et al. Fit genotypes and escape variants of subgroup III Neisseria manigitidis during three pandemics of epidemic meningitis. Proc Natl Acad Sci USA 2001;98:5234-5239.
20. Diermayer M, Hedberg K, Hoesly F, Fischer M, Perkins B, Reeves M, Fleming D. Epidemic serogroup B meningococcal disease in Oregon: the evolving epidemiology of the ET-5 strain. JAMA 1999;281:1541-1543.
21. Nicolas P, Decousset L, Riglet V, Castelli RS, Blanchet G. Clonal expansion of sequence type (ST)-5 and the emergence of ST-7 in serogroup A meningococci, Africa. Emerg Infect Dis 2001;7:849-854.
22. Pollard AJ, Scheifele D. Meningococcal disease and vaccination in North America. J Paediatr Child Health 2001;37:520-527.
23. Wang JF, Caugant DA, Morelli G, Koumare B, Achtman M. Antigenic and epidemiological properties of the ET-37 complex of Neisseria meningitidis. J Infect Dis 1993;167:1320-1329.
24. Vogel U, Claus H, Frosch M. Rapid serogroup switching in Neisseria meningitidis. N Engl J Med 2000;342:219-20.
25. Peltola H, Jonsdottir K, Lystad A, Sievers CJ, Kallings I. Meningococcal disease in Scandinavia. BMJ 1982;284:1618-1621.
26. Wang J, Caugant DA, Li X, et al. Clonal and antigenic analysis of serogroup A Neisseria meningitidis with particular reference to epidemiological features of epidemic meningitis in China. Infect Immun 1992;60:5267-5282.
27. Cartwright K. Meningococcal carriage and disease. In: Cartwright K, editor. Meningococcal disease, 1st ed. Chicester: Wiley; 1995. p. 115-145.
28. Kwara A, Adegbola RA, Corrah PT, Weber M, Achtman M, Morelli G, Caugant DA, Greenwood BM. Meningitis caused by a serogroup W135 clone of the ET-37 complex of Neisseria meningitidis in West Africa. Trop Med Int Child Health 1998;3:742-746.
29. World Health Organisation, Outbreaks. Wkly Epidemiol Rec 2000;75:117-118.
30. Evans JR, Artenstein MS, Hunter DH. Prevalence of meningococcal serogroups and description of three new groups. Am J Epidemiol 1968;87:643-646.
31. Brandstetter RD, Blair RJ, Roberts RB. Neisseria meningitidis serogroup W135 disease in adults. JAMA 1981;246:2060-2061.
32. World Health Organisation, Outbreaks. Wkly Epidemiol Rec 2000;75:180.
33. Yousouf M, Nadeem A. Fatal meningococcaemia due to group W135 amongst Hajj pilgrims: implications for future vaccination policy. Ann Trop Med Parasitol 1995;89:321-322.
34. Denis L, Rey JL, Amadou A, Saliou P, Prince-David M, M'Boup S, et al. Emergence of meningococcal meningitis caused by W135 serogroup in Africa. Lancet 1982;ii:1335-1336.
35. Cadoz M, Denis F, Mar ID. An epidemiological study of purulent meningitis cases admitted to hospital in Dakar: 1970-79. Bull World Health Org 1981;59:575-584.
36. Riou JY, Saliou P, Guibourdenche M, Chalvignac MA. Etude bacteriologique de 358 souches de Neisseria et branhamella isolees en Haute Volta. Med Mal Infect 1980;10:430-436.
37. Greenwood BM, Smith AW, Hassan-King M, Bijlmer HA, Shenton FC, Hughes AS, Nunn PP, Jack AD, Gowers PR. The efficacy of meningococcal polysaccharide vaccine in preventing group A meningococcal disease in The Gambia, West Africa. Trans R Soc Trop Med Hyg 1986;80:1006-7.
38. Guibourdenche M, Hoiby EA, Riou J-Y, Varaine F, Joguet C, Caugant DA. Epidemics of serogroup A Neisseria meningitidis of subgroup III in Africa, 1989-94. Epidemiol Infect 1996;116:115-120.
39. MacLennan JM, Urwin R, Obaro S, Griffiths D, Greenwood B, Maiden MCJ. Carriage of serogroup W-135, ET-37 meningococci in The Gambia: implications for immunisation policy? Lancet 2000;356:1078.
40. Fonkoua M-C, Taha M-K, Nicolas P, Cunin P, Alonso J-M, et al. Recent increase in meningitis caused Neisseria meningitidis serogroups A and W135, Yaounde, Cameroon. Emerg Inf Dis 2002;8:327-329.
41. Taha M-K, Parent du Chatelet I, Schlumberger M, Sanou I, Djibou S, de Chabalier F, Alonso J-M. Neisseria meningitidis serogroups W135 and A were equally prevalent among meningitis cases occurring at the end of the 2001 epidemics in Burkina Faso and Niger. J Clin Microbiol 2002;40:1083-1084.
42. World Health Organisation, Epidemics of meningococcal disease, African meningitis belt. Wkly Epidemiol Rec 2001;37:218-288.
43. Decosas J, Koama J-BT. Chronicle of an outbreak foretold: meningococcal meningitis W135 in Burkina Faso. Lancet Infect Dis 2002;2:763-765.
44. Jodar L, Feavers IM, Salisbury D, Granoff DM. Development of vaccines against meningococcal disease. Lancet 2002;359:1499-1508.
45. Brundage JF, Ryan MAK, Feighner BH, Erdtmann FJ. Meningococcal disease among United States military service members in relation to routine uses of vaccines with different serogroup-specific components, 1964-1998. Clin Infect Dis 2002;35:1376-1381.
46. Morley SL, Pollard AJ. Vaccine prevention of meningococcal disease, coming soon? Vaccine 2001;20:666-687.
47. Lewis R, Nathan N, Diarra L, Belanger F, Paquet C. Timely detection of meningococcal meningitis epidemics in Africa. Lancet 2001;358:287-293.
48. Correspondence, Meningococcal immunisation in Ghana. Lancet 2000;355:2252-2253.
49. Griffiss JM, Brandt BL, Broud DD. Human immune response to various doses of Y and W135 meningococcal polysaccharide vaccines. Infect Immun 1982;37:205-208.
50. Peltola H, Safary A, Kayhty H, Karanko V, Andre F. Evaluation of two tetravalent (ACYW135) meningococcal vaccines in infants and small children: A clinical study comparing immunogenicity of O-acetyl-negative and O-acetyl-positive group C polysaccharides. Pediatrics 1985;76:91-96.
51. News, Vaccine campaign reduces illness in travellers. BMJ 2000;356:120.
52. Rennels M, King Jr J, Ryall R, et al. Dose escalation, safety and immunogenicity study of a tetravalent meningococcal polysaccharide diphtheria conjugate vaccine in toddlers. Paediatr Infect Dis J 2002;21:978-979.
53. Campbell JD, Edelman King Jr JC, Papa T, Ryall R, Rennels MB. Safety, reactogenicity and immunogenicity of a tetravalent meningococcal polysaccharide-diphtheria toxoid conjugate vaccine given to healthy adults. J Infect Dis 2002;186:1848-1851.
54. Pollard AJ, Maiden MCJ. Epidemic meningococcal disease in sub-Saharan Africa-towards a sustainable solution? Lancet Infect Dis 2003;3:69-70.
55. Maiden MJC, Spratt BG. Meningococcal conjugate vaccines: new opportunities and new challenges. Lancet 1999;354:615-616.
56. Baker P, Borrow R, Miller E. Impact of meningococcal C conjugate vaccination in the UK. J Med Microbiol 2002;51:717-722.
57. Trotter CL, Ramsay ME, Kaczmarski EB. Meningococcal serogroup C conjugate vaccination in England and Wales: coverage and initial impact of the campaign. Commun Dis Public Health 2002;5:220-225.
58. Obaro SK, Adegbola RA, Banya WA, Greenwood BM. Carriage of pneumococci after pneumococcal vaccination. Lancet 1996;348:271-272.
59. Rosenstein NE, Perkins BA, Stephens DS, Lefkowitz L, Cartter ML, Danila R, et al. The changing epidemiology of meningococcal disease in the United States 1992-1996. J Infect Dis 1999;180:1894-1901.
60. Gotschlich EC, Goldschneider I, Artenstein MS. Human immunity to meningococcus. V. The effect of immunization with meningococcal group C polysaccharide on the carrier state. J Exp Med 1969;129:1385-1395.
61. Artenstein MS, Gold R, Zimmerly JG, Wyle FA, Schneider H, Harkins C. Prevention of meningococcal disease by group C polysaccharide vaccine. N Engl J Med 1970;282:417-420.
62. Sivonen A. Effect of Neisseria meningitidis group A polysaccharide vaccine on nasopharyngeal carrier rates. J Infect 1981;3:266-272.
63. Gagneux S, Wirth T, Hodgson A, Ehrhard I, Morelli G, Kriz P, Genton B, Smith T, Binka F, Pluschke G, Achtman M. Clonal groupings in serogroup X Neisseria meningitidis. Emerg Infect Dis 2002;8.